SCHEMBL10190197

SCHEMBL10190197

CC(C)(C)OC(=O)N1CC(Sc2ccc(C(=O)N3CCCC3)cc2)C1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.58
MEN1 O00255 6/20 0.58
ABL1 P00519 1/20 0.56
RIN1 Q13671 1/20 0.56
HPGD P15428 8/20 0.46
ALDH1A1 P00352 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
HTT P42858 2/20 0.45
EPHX2 P34913 1/20 0.44
MAPT P10636 2/20 0.43
RAB9A P51151 1/20 0.43
HDAC4 P56524 1/20 0.43
GPR119 Q8TDV5 1/20 0.43
KDM4E B2RXH2 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MLYCD O95822 1/20 0.43
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL322089 0.84 USP30 (0.45) KMT2AMEN1GPR119KDM4E
SCHEMBL10190187 0.82 NR1H2 (0.43) KMT2AMEN1ALDH1A1MAPTGPR119
SCHEMBL321919 0.81 HPGD (0.54) KMT2AMEN1HPGDALDH1A1SMN1; SMN2
SCHEMBL26966923 0.81 ESR2 (0.46) KMT2AGPR119KDM4E
SCHEMBL16422836 0.80 HDAC1 (0.47) KMT2AMEN1GPR119
SCHEMBL12284229 0.80 RORC (0.48) GPR119KDM4E
SCHEMBL17541949 0.80 NR1H2 (0.47) ALDH1A1HTTMAPTRAB9AGPR119
SCHEMBL15212446 0.80 RORC (0.50) GPR119KDM4E
SCHEMBL23204176 0.78 POLB (0.46) KMT2AMEN1ABL1RIN1HPGD
SCHEMBL21426511 0.78 POLB (0.46) KMT2AMEN1ABL1RIN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590969-B1 Therapeutic agents 976 ASTRAZENECA AB (SE) 2014-10-15 EP disclosed
US-8546375-B2 (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds ASTRAZENECA AB (SE) 2013-10-01 US disclosed
US-8546375-B2 (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds ASTRAZENECA AB (SE) 2013-10-01 US disclosed
US-20120010189-A1 (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS ASTRAZENECA AB (SE) 2012-01-12 US disclosed
US-20120010189-A1 (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS ASTRAZENECA AB (SE) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010189-A1 (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS TYR, MC2R, MC1R KMT2A 2009/4885MEN1 101/4885ABL1 2377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.